Aging and bone loss: new insights for the clinician
暂无分享,去创建一个
[1] S. Khosla,et al. Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. , 2006, The Journal of clinical endocrinology and metabolism.
[2] G. Duque,et al. Alendronate Has an Anabolic Effect on Bone Through the Differentiation of Mesenchymal Stem Cells , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] G. Duque,et al. Age-related changes in lamin A/C expression in the osteoarticular system: Laminopathies as a potential new aging mechanism , 2006, Mechanisms of Ageing and Development.
[4] B. Riggs,et al. Pathophysiology of age-related bone loss and osteoporosis. , 2005, Endocrinology and metabolism clinics of North America.
[5] P. Lips. Vitamin D status and nutrition in Europe and Asia , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[6] L. Mosekilde,et al. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis , 2004, Biogerontology.
[7] S. Mohan,et al. Concentrations of insulin-like growth factor (IGF)-I, -II, and IGF binding protein-4, and -5 in human bone cell conditioned medium do not change with age , 2000, Mechanisms of Ageing and Development.
[8] B. Riggs,et al. The role of the immune system in the pathophysiology of osteoporosis , 2005, Immunological reviews.
[9] J. Caverzasio. Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. , 2008, Bone.
[10] D. Schoenfeld,et al. Differential effects of androgens and estrogens on bone turnover in normal men. , 2003, The Journal of clinical endocrinology and metabolism.
[11] L. Melton,et al. Involutional osteoporosis. , 1986, The New England journal of medicine.
[12] Pierre Cau,et al. Lamin A Truncation in Hutchinson-Gilford Progeria , 2003, Science.
[13] O. MacDougald,et al. Regulation of bone mass by Wnt signaling. , 2006, The Journal of clinical investigation.
[14] B. Clarke. Older Men With Low Serum Estradiol and High Serum SHBG Have an Increased Risk of Fractures , 2009 .
[15] M. Jensen,et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. , 1999, Endocrinology.
[16] L. Duong,et al. Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies , 2009, Clinical pharmacology and therapeutics.
[17] Dennis E. Discher,et al. Physical plasticity of the nucleus in stem cell differentiation , 2007, Proceedings of the National Academy of Sciences.
[18] R. Baron,et al. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. , 2002, European journal of pharmacology.
[19] L. McCabe,et al. Inhibition of PPARγ prevents type I diabetic bone marrow adiposity but not bone loss , 2006, Journal of cellular physiology.
[20] A. Economides,et al. 0163-769X/03/$20.00/0 Endocrine Reviews 24(2):218–235 Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/er.2002-0023 Bone Morphogenetic Proteins, Their Antagonists, and the Skeleton , 2022 .
[21] C. Slemenda,et al. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. , 1996, The Journal of clinical investigation.
[22] L. Suva,et al. Aging alters the skeletal response to disuse in the rat. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[23] Wei Li,et al. Age-related bone loss in the LOU/c rat model of healthy ageing , 2009, Experimental Gerontology.
[24] P Geusens,et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.
[25] M. Macoritto,et al. Interferon‐γ plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[27] J. Bilezikian,et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy , 2007, Osteoporosis International.
[28] M. Kneissel. The promise of sclerostin inhibition for the treatment of osteoporosis , 2009 .
[29] P. Kostenuik,et al. Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[30] P. Tugwell,et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2024, The Cochrane database of systematic reviews.
[31] Qing Chen,et al. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[32] C. Slemenda,et al. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. , 1997, The Journal of clinical investigation.
[33] Dami,et al. EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN , 2001 .
[34] B. L. Riggs,et al. Effect of Blockade of TNF‐α and Interleukin‐1 Action on Bone Resorption in Early Postmenopausal Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] J. Henderson,et al. Accelerated features of age-related bone loss in zmpste24 metalloproteinase-deficient mice. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.
[36] C. Ackert-Bicknell,et al. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. , 2009, Critical reviews in eukaryotic gene expression.
[37] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[38] D. Fisher,et al. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. , 2002, Current molecular medicine.
[39] H. Kemper,et al. The Effect of Exercise Training Programs on Bone Mass: A Meta-analysis of Published Controlled Trials in Pre- and Postmenopausal Women , 1999, Osteoporosis International.
[40] Kozo Nakamura,et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts , 2002, The Journal of cell biology.
[41] R. Lindsay,et al. Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis , 2007, Annals of Internal Medicine.
[42] P. Marie,et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. , 1996, Bone.
[43] A. Oberg,et al. Role of parathyroid hormone in mediating age-related changes in bone resorption in men , 2003, Osteoporosis International.
[44] E. Seeman,et al. Causes of Age‐Related Bone Loss and Bone Fragility: An Alternative View , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[45] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[46] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[47] J. Dungan. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis , 2010 .
[48] D. Lacey,et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.
[49] R. Rizzoli,et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[50] P. Delmas,et al. Influence of mature adipocytes on osteoblast proliferation in human primary cocultures. , 2000, Bone.
[51] J. Gimble,et al. Playing with bone and fat , 2006, Journal of cellular biochemistry.
[52] P Meunier,et al. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. , 1971, Clinical orthopaedics and related research.
[53] D. Fatkin,et al. Attenuated anabolic response to exercise in lamin A/C haploinsufficient mice. , 2011, Bone.
[54] D. Brömme,et al. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. , 2005, Advanced drug delivery reviews.
[55] P. Tugwell,et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.
[56] A Simkin,et al. Gain in mass density of bone following strenuous physical activity , 1989, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[57] E. Seeman. From Density to Structure: Growing Up and Growing Old on the Surfaces of Bone , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[58] B. Riggs,et al. Relation of Serum Serotonin Levels to Bone Density and Structural Parameters in Women , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[59] B. Clarke,et al. Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial , 2008 .
[60] Sundeep Khosla,et al. Population‐Based Study of Age and Sex Differences in Bone Volumetric Density, Size, Geometry, and Structure at Different Skeletal Sites , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[61] D. Felson,et al. Osteoporosis in Men , 2001, Journal of the Royal Society of Medicine.
[62] S. Goldstein,et al. Transgenic Models of Metabolic Bone Disease: Impact of Estrogen Receptor Deficiency on Skeletal Metabolism , 2003, Connective tissue research.
[63] K. Smans,et al. Neuro-hormonal control of bone metabolism: vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation mineralized bone nodules , 1999, Regulatory Peptides.
[64] B. Troen,et al. Understanding the Mechanisms of Senile Osteoporosis: New Facts for a Major Geriatric Syndrome , 2008, Journal of the American Geriatrics Society.
[65] Giselle Chamberlain,et al. Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing , 2007, Stem cells.
[66] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[67] A. Grey. Skeletal consequences of thiazolidinedione therapy , 2008, Osteoporosis International.
[68] G. Duque. As a matter of fat: New perspectives on the understanding of age-related bone loss , 2007 .
[69] L. Donahue,et al. Insulin-like Growth Factors and Bone: The Osteoporosis Connection , 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[70] P. Lips,et al. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. , 2001, Endocrine reviews.
[71] Sundeep Khosla,et al. Sex steroids and the construction and conservation of the adult skeleton. , 2002, Endocrine reviews.
[72] Ego Seeman,et al. Pathogenesis of bone fragility in women and men , 2002, The Lancet.
[73] J. Launay,et al. In vitro production of cytokines by bone surface-derived osteoblastic cells in normal and osteoporotic postmenopausal women: relationship with cell proliferation. , 1993, The Journal of clinical endocrinology and metabolism.
[74] R. Considine,et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.
[75] S. Boonen,et al. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. , 2007, The New England journal of medicine.
[76] D. Lacey,et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.
[77] J. Reginster,et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.
[78] J. Reginster,et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. , 2009, Bone.
[79] Chao Wan,et al. Oxygen Sensing and Osteogenesis , 2007, Annals of the New York Academy of Sciences.
[80] M. Burritt,et al. Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. , 1995, The Journal of clinical endocrinology and metabolism.
[81] K. Lindpaintner,et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease , 2002, Journal of medical genetics.
[82] C. Becker. Another selective estrogen-receptor modulator for osteoporosis. , 2010, The New England journal of medicine.
[83] L. Melton,et al. High Serum IGFBP‐2 Is Predictive of Increased Bone Turnover in Aging Men and Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[84] L. Melton,et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. , 2001, The Journal of clinical endocrinology and metabolism.
[85] D. Lacey,et al. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors , 1999, Journal of cellular biochemistry.
[86] T. Spector,et al. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.
[87] S. Berney,et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis , 2008 .
[88] Patricia Ducy,et al. Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.
[89] M. Rybchyn,et al. Osteoblasts play key roles in the mechanisms of action of strontium ranelate , 2009, British journal of pharmacology.
[90] J Reeve,et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. , 1980, British medical journal.
[91] J. Kaufman,et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy , 2005, Osteoporosis International.
[92] Arndt F Schilling,et al. Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.
[93] Ping Chung Leung,et al. Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. , 2005, Radiology.
[94] M. Kumegawa,et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. , 2000, Bone.
[95] M. Hiligsmann,et al. Strontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis , 2010, Therapeutic advances in musculoskeletal disease.
[96] Joel S Greenberger,et al. Age‐related intrinsic changes in human bone‐marrow‐derived mesenchymal stem cells and their differentiation to osteoblasts , 2008, Aging cell.
[97] J. Reginster,et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial , 2009, The Lancet.
[98] P. Lehenkari,et al. Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase-Activating Peptide Receptor Subtypes in Mouse Calvarial Osteoblasts: Presence of VIP-2 Receptors and Differentiation-Induced Expression of VIP-1 Receptors * * The present study was supported by grants from the Swedish Medical Research C , 2001, Endocrinology.
[99] C. Christiansen,et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[100] D. Reid,et al. Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid‐Induced Osteoporosis in Men and Women: A Randomized Trial , 2000 .
[101] George P Chrousos,et al. Positive Linear Growth and Bone Responses to Growth Hormone Treatment in Children With Types III and IV Osteogenesis Imperfecta: High Predictive Value of the Carboxyterminal Propeptide of Type I Procollagen , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[102] S. B. Heymsfield,et al. MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women , 2007, Osteoporosis International.
[103] H. Worman,et al. A-type lamins: Guardians of the soma? , 2004, Nature Cell Biology.
[104] G. Duque,et al. Severe bone changes in a case of Hutchinson-Gilford syndrome. , 2002, Annales de genetique.
[105] G. Rodan,et al. Osteopenia in the immobilized rat hind limb is associated with increased bone resorption and decreased bone formation. , 1989, Bone.
[106] B. Troen. The role of cathepsin K in normal bone resorption. , 2004, Drug news & perspectives.
[107] R. Eastell,et al. Interrelationship among vitamin D metabolism, true calcium absorption, parathyroid function, and age in women: Evidence of an age‐related intestinal resistance to 1,25‐dihydroxyvitamin D action , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[108] W. Vollmer,et al. Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density. , 1995, The Journal of clinical endocrinology and metabolism.
[109] G. Mundy,et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.
[110] J. Eisman,et al. Volumetric bone density at the femoral neck as a common measure of hip fracture risk for men and women. , 2004, The Journal of clinical endocrinology and metabolism.
[111] J Denton,et al. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis , 2002, Journal of clinical pathology.
[112] S. Friedman,et al. Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. , 2001, American journal of physiology. Endocrinology and metabolism.
[113] S. Silverman,et al. Anabolic Therapies , 2010, Current osteoporosis reports.
[114] A. Oberg,et al. Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. , 2005, The Journal of clinical endocrinology and metabolism.
[115] B. Riggs,et al. Comparison of sex steroid measurements in men by immunoassay versus mass spectroscopy and relationships with cortical and trabecular volumetric bone mineral density , 2008, Osteoporosis International.
[116] B. Clarke,et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial , 2009 .
[117] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.
[118] R. Russell,et al. Bisphosphonates: from bench to bedside. , 2006, Annals of the New York Academy of Sciences.
[119] D. Fatkin,et al. Decreased Bone Formation and Osteopenia in Lamin A/C-Deficient Mice , 2011, PloS one.
[120] G. Verbeke,et al. Down‐Regulation of the Serum Stimulatory Components of the Insulin‐like Growth Factor (IGF) System (IGF‐I, IGF‐II, IGF Binding Protein [BP]‐3, and IGFBP‐5) in Age‐Related (Type II) Femoral Neck Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[121] X. Guo,et al. Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo , 2008, Proceedings of the National Academy of Sciences.
[122] L. Melton,et al. Relationship between body composition and bone mass in women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[123] R. Lindsay,et al. Bone mass and body composition in normal women. , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[124] E. Posvar,et al. Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[125] Jacques P. Brown,et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. , 2001, Arthritis and rheumatism.
[126] B. Troen. The Regulation of Cathepsin K Gene Expression , 2006, Annals of the New York Academy of Sciences.
[127] P. Halbout,et al. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response , 2009, Osteoporosis International.
[128] J J Anderson,et al. Effects of weight and body mass index on bone mineral density in men and women: The framingham study , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[129] L. Suva,et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. , 2007, Endocrinology.
[130] D. Reid,et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[131] B. Lecka-Czernik. PPARs and Bone Metabolism , 2006, PPAR research.
[132] J. Eisman,et al. Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[133] R. Eastell,et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. , 2000, The Journal of clinical investigation.
[134] L. Melton,et al. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. , 1997, The Journal of clinical endocrinology and metabolism.
[135] E. Orwoll,et al. Alendronate for the treatment of osteoporosis in men. , 2000, The New England journal of medicine.
[136] L. Mounkes,et al. A progeroid syndrome in mice is caused by defects in A-type lamins , 2003, Nature.
[137] Guoyin Feng,et al. Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β‐Catenin Signaling , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[138] N. Takahashi,et al. S 12911‐2 Inhibits Osteoclastic Bone Resorption In Vitro , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[139] Y. Wan,et al. PPAR-γ regulates osteoclastogenesis in mice , 2007, Nature Medicine.
[140] M Dioszegi,et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.
[141] W. Rifkin. Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.
[142] E. Barrett-Connor,et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. , 2009, The Journal of clinical endocrinology and metabolism.
[143] P. Delmas,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Bioavailable Estradiol May Be an Important Determinant of Osteoporosis in Men: The MINOS Study* , 2022 .
[144] B. Riggs,et al. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[145] Kenji F. Tanaka,et al. A Serotonin-Dependent Mechanism Explains the Leptin Regulation of Bone Mass, Appetite, and Energy Expenditure , 2009, Cell.
[146] B. Langdahl,et al. Medical Treatment of Osteoporotic Vertebral Fractures , 2011, Therapeutic advances in musculoskeletal disease.
[147] S. Khosla. Update in male osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.
[148] S. Khosla,et al. Physiology of bone loss. , 2010, Radiologic clinics of North America.
[149] B. Baggio,et al. Effects of Unsaturated Free Fatty Acids on Adhesion and on Gene Expression of Extracellular Matrix Macromolecules in Human Osteoblast-like Cell Cultures , 2007, Connective tissue research.
[150] P. Tugwell,et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.
[151] P. Lehenkari,et al. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. , 2001, Endocrinology.
[152] Mary L Bouxsein,et al. Mechanisms of Disease: is osteoporosis the obesity of bone? , 2006, Nature Clinical Practice Rheumatology.
[153] S. Boonen,et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. , 2007, The New England journal of medicine.